Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Major Purchasers Taking Advantage of Consumption Tax Labeling Change
March 8, 2004
- Aiming to Strengthen R&D Capability, Independent Sales Forces Abroad: Yamanouchi, Fujisawa
March 8, 2004
- OTC NEWS IN BRIEF
March 8, 2004
- Allegra, Alesion Are Doctors' 1st Choice Prescriptions for Pollinosis: PJ, So-net M3 Survey
March 8, 2004
- WORLD NEWS IN BREIF
March 8, 2004
- Chugai Aims at Top in Priority Fields: Cancer, Nephropathy, Bone
March 1, 2004
- Taisho: Downward Revisions in FY2003 Business Forecast
March 1, 2004
- 1st 3 Qtrs Business Results
March 1, 2004
- 1st Qtrs Business Results
March 1, 2004
- BULLETIN
March 1, 2004
- Sankyo to Conduct Large-scale Clinical Study on Olmesartan
March 1, 2004
- BULLETIN
March 1, 2004
- Tanabe Receives Monkasho Approval for Human ES Cell Study
March 1, 2004
- Meropen IV Gets Remedy of Purulent Meningitis as Add. Indication
March 1, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 1, 2004
- Chuikyo Approves FY2004 Medical Fee Revision Proposal
March 1, 2004
- OTC NEWS IN BRIEF
March 1, 2004
- REGULATORY NEWS IN BRIEF
March 1, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 1, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 1, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…